Summary

for people ages 18-99 (full criteria)
at UCLAUCSF
study started
estimated completion

Description

Summary

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Official Title

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Details

This is a multicenter, open-label, dose-escalation, and dose expansion study of MEDI4736 in combination with tremelimumab to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult subjects with advanced NSCLC.

Keywords

NSCLCNon-small Cell Lung CancerLung Canceranti-CTLA-4anti-PD-L1immunotherapyIMTCLung NeoplasmsCarcinoma, Non-Small-Cell LungDurvalumabTremelimumabAntibodies, MonoclonalMEDI4736Dose Escalation

Eligibility

You can join if…

Open to people ages 18-99

  1. Age ≥ 18 years
  2. Advanced non-small cell lung cancer
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  4. Adequate organ and marrow function

You CAN'T join if...

  1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
  2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs
  3. Active or prior documented autoimmune disease within the last 2 years.

Locations

  • Research Site
    Los AngelesCalifornia90095United States
  • Research Site
    Los AngelesCalifornia90025United States
  • Research Site
    San FranciscoCalifornia94158United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MedImmune LLC
ID
NCT02000947
Phase
Phase 1
Study Type
Interventional
Last Updated